Multiple Myeloma Coverage from Every Angle

Sagar Lonial, MD, on Lenalidomide vs Observation Alone in High-Risk Smoldering Multiple Myeloma

Posted: Monday, June 17, 2019

Sagar Lonial, MD, of Winship Cancer Institute of Emory University, discusses whether study findings should alter the standard approach of observation alone with lenalidomide treatment which may delay progression of asymptomatic high-risk smoldering multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.